As of June 9, 2025, Sio Gene Therapies Inc (SIOX) reports a ROE (Return on Equity) of -119.22%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Sio Gene Therapies Inc's ROE (Return on Equity)
Over recent years, Sio Gene Therapies Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-03-31 | -119.22% |
| 2021-03-31 | -26.28% |
| 2020-03-31 | -117.91% |
| 2019-03-31 | -229.66% |
| 2018-03-31 | -310.76% |
This slight downward trend highlights how Sio Gene Therapies Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Sio Gene Therapies Inc's ROE (Return on Equity) to Peers
To better understand Sio Gene Therapies Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Sio Gene Therapies Inc (SIOX) | -119.22% |
| Oragenics Inc (OGEN) | 4987.46% |
| GT Biopharma Inc (GTBP) | 788.14% |
| ContraFect Corp (CFRX) | 549.79% |
| Abbvie Inc (ABBV) | 128.66% |
| Xynomic Pharmaceuticals Holdings Inc (XYNO) | 111.26% |
Compared to its competitors, Sio Gene Therapies Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.